Ginkgo Bioworks: Unproven Transition But 2025 Is Looking Better
Analysis of Ginkgo Bioworks' Q3 results and business model, with a focus on growth, customer acquisition and cash flow ...
Ginkgo Bioworks price target lowered to $6 from $7 at BTIG
BTIG analyst Mark Massaro lowered the firm’s price target on Ginkgo Bioworks (DNA) to $6 from $7 and keeps a Sell rating on the shares ...
Struggling Ginkgo Bioworks says it will step away from soon-to-open Seaport building
One of the few bright spots in Boston’s life-science lab space market this year has dimmed.
Morningstar3d
Ginkgo Bioworks Holdings Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Investing3d
Ginkgo Bioworks Holdings (DNA)
In a recent transaction, Steven P. Coen, the Chief Accounting Officer of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), sold shares of the company's stock, reportedly to cover tax ...
Ginkgo Bioworks: Not Enough Progress
Ginkgo Bioworks reported mixed Q3, with a $45M one-time revenue boost masking underlying revenue growth issues. Read why I ...
Ginkgo cancels move to new South Boston lab, exits Cambridge office
Ginkgo Bioworks is headquartered at 27 Drydock Avenue in Boston's Seaport. Ginkgo has canceled its planned move into a ...
Insights into Ginkgo Bioworks Holdings's Upcoming Earnings
Return on Assets (ROA): Ginkgo Bioworks Holdings's ROA lags behind industry averages, suggesting challenges in maximizing ...
24/7 Wall St3d
Ginkgo Bioworks Holdings Inc - Class A
Ginkgo Bioworks Holdings Inc, based in Boston, Massachusetts, specializes in cell programming to revolutionize the production of various products. By manipulating cells, they create novel ...